About Abeona Therapeutics Inc.
https://www.abeonatherapeutics.comAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa.
CEO
Vishwas Seshadri
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-07-05 | Reverse | 1:25 |
| 2014-10-24 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 3 of 55
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
QS INVESTORS, LLC
Shares:325K
Value:$1.69M
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.
Shares:202.55K
Value:$1.05M
TEACHERS ADVISORS, LLC
Shares:98.19K
Value:$509.62K
Summary
Showing Top 3 of 12
About Abeona Therapeutics Inc.
https://www.abeonatherapeutics.comAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 ▼ | $23.53M ▲ | $-5.16M ▼ | 0% ▼ | $-0.1 ▼ | $-18.57M ▼ |
| Q2-2025 | $400K ▲ | $23.09M ▲ | $108.83M ▲ | 27.21K% ▲ | $2.07 ▲ | $126.07M ▲ |
| Q1-2025 | $0 | $19.73M ▲ | $-12.03M ▼ | 0% | $-0.24 ▼ | $-10.22M ▼ |
| Q4-2024 | $0 | $15.9M ▲ | $-9.29M ▲ | 0% | $-0.23 ▲ | $-7.44M ▲ |
| Q3-2024 | $0 | $15.35M | $-30.27M | 0% | $-0.63 | $-28.45M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $207.46M ▼ | $231.09M ▼ | $59.86M ▼ | $171.23M ▲ |
| Q2-2025 | $225.52M ▲ | $246.23M ▲ | $82.66M ▲ | $163.58M ▲ |
| Q1-2025 | $84.16M ▼ | $99.36M ▼ | $57.97M ▼ | $41.4M ▼ |
| Q4-2024 | $97.72M ▼ | $108.93M ▼ | $64.9M ▼ | $44.03M ▼ |
| Q3-2024 | $109.7M | $120.59M | $74.82M | $45.77M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-5.16M ▼ | $-21.19M ▼ | $-64.63M ▼ | $5.16M ▼ | $-80.65M ▼ | $-23.71M ▼ |
| Q2-2025 | $108.83M ▲ | $-18.78M ▼ | $155.89M ▲ | $10.49M ▲ | $147.6M ▲ | $-21.68M ▼ |
| Q1-2025 | $-12.03M ▼ | $-18.4M ▼ | $4.21M ▼ | $6.77M ▲ | $-7.42M ▼ | $-19.8M ▼ |
| Q4-2024 | $-9.29M ▲ | $-16.56M ▼ | $18.88M ▲ | $5.31M ▲ | $7.63M ▲ | $-17.16M ▼ |
| Q3-2024 | $-30.27M | $-12.23M | $-6.17M | $-299K | $-18.7M | $-12.64M |
Revenue by Products
| Product | Q2-2018 | Q3-2018 | Q4-2018 |
|---|---|---|---|
 Grant | $0 ▲ | $0 ▲ | $0 ▲ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Vishwas Seshadri
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-07-05 | Reverse | 1:25 |
| 2014-10-24 | Reverse | 1:50 |
ETFs Holding This Stock
Summary
Showing Top 3 of 55
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
QS INVESTORS, LLC
Shares:325K
Value:$1.69M
BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.
Shares:202.55K
Value:$1.05M
TEACHERS ADVISORS, LLC
Shares:98.19K
Value:$509.62K
Summary
Showing Top 3 of 12